BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Gilead Sciences Stock Dips as CVS Rejects HIV Prevention Drug
Gilead Sciences Stock Dips as CVS Rejects HIV Prevention Drug
14
3
BTCCSquare news:
Gilead Sciences shares fell 1% after CVS Health declined to include its new HIV prevention drug, Yeztugo, in commercial plans. The decision, based on clinical, financial, and regulatory factors, marks a setback despite FDA approval in June.
Yeztugo, an injectable treatment for HIV prevention, showed 99.9% efficacy in trials. Gilead had hailed its approval as a historic milestone, but CVS's refusal to cover it under ACA formularies dampens near-term prospects.
By:
